Driving Efficiency, Reducing Costs In Multi-Modal CGT Manufacturing

As CGT pipelines diversify, many biotechs are outsourcing production of multiple modalities to the same manufacturing partner. Understanding how those partners manage risk, optimize facility space, and control costs is critical to protecting CGT companies’ products and patients.

On this Cell & Gene Live, Erin Harris, Chief Editor of Cell & Gene welcomed Steve Awad, Principal Director, Supply Chain & Industry X — Life Sciences at Accenture, and Michael Blackton MBA, VP, Manufacturing and Supply at Ocugen as they unpacked what CGT developers need to know about efficient, compliant dual- or multi-modal manufacturing even when production is outsourced. They covered why non-viral and electroporation-based modalities can simplify outsourced manufacturing and reduce cost and complexity along with the right questions to ask when evaluating a CDMO’s contamination control and capacity strategy.